Qube Research & Technologies LTD Halozyme Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
A detailed history of Qube Research & Technologies LTD transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 40,872 shares of HALO stock, worth $2.44 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,872
Previous 363,339
88.75%
Holding current value
$2.44 Million
Previous $14.8 Million
85.52%
% of portfolio
0.0%
Previous 0.02%
Shares
17 transactions
Others Institutions Holding HALO
# of Institutions
526Shares Held
123MCall Options Held
208KPut Options Held
77.1K-
Black Rock Inc. New York, NY17.6MShares$1.05 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$768 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$347 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$241 Million4.92% of portfolio
-
Alliancebernstein L.P. New York, NY3.55MShares$212 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.3B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...